An assessment of SSTR receptor subtypes in NETs revealed that 51% of cases highly expressed SSTR2, 47% SSTR1, 43% SSTR5, 36% SSTR4, and 23% SSTR3.3 A high expression of both SSTR1 and SSTR2 was found more frequently in pancreatic NETs and small intestinal NETs than in other NETs.3 It is important to note that octreotide and lanreotide, both of which are synthetic somatostatin analogs (SSAs), primarily bind to SSTR2 and SSTR5.3 The gene discussed is SSTR2; the disease is pancreatic neuroendocrine tumor.